Abstract
Glottic squamous cell carcinoma is a disease with good life prognosis, but local recurrence of 30% has been reported in cases of treatment with radiotherapy alone. For the purpose of enhancing local control and the preservation rate of the larynx, oral anticancer drug S-1 has been administered in addition to radiotherapy. Twenty-seven patients who received concurrent radiotherapy with S-1 at our hospital between April 2004 and July 2010 were examined. The dose of S-1 was calculated based on the body surface area and reduced by one level from the initial reference amount (80-100 mg/day), and it was administered for 2 weeks followed by a 1-week rest period during the radiotherapy. The 5-year disease-specific survival rate and larynx preservation rate were 100% and 88.2%, respectively. Adverse events of Grade 3 or higher included 10 cases of dermatitis, 7 cases of mucositis, and 1 case each of leukopenia, infection and diarrhea. There was no termination or discontinuation of radiotherapy. Concurrent radiotherapy with S-1 for T2N0 glottic cancer was considered to be a manageable and useful treatment.
